Timothy A. Springer - 02 Jan 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role: Director, 10%+ Owner
Signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Issuer symbol: RNAC
Transactions as of: 02 Jan 2025
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2025, 16:19:59 UTC
Previous filing: 23 Dec 2024
Next filing: 15 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNAC	Common Stock	Award	$0	+2,600	+0.03%	$0.000000	8,510,495	02 Jan 2025	Direct	F1
holding	RNAC	Common Stock						330,695	02 Jan 2025	By wife
holding	RNAC	Common Stock						529,798	02 Jan 2025	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAC	Stock Option (Right to Buy)	Award	$0	+7,800		$0.000000	7,800	02 Jan 2025	Common Stock	7,800	$16.93	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.
F2	Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.